Breast Cancer Intravoxel-incoherent-motion MRI Multisite (BRIMM) Study - Resubmission - 1

NIH RePORTER · NIH · UG3 · $395,274 · view on reporter.nih.gov ↗

Abstract

PROJECT SUMMARY While the technological enterprise of magnetic resonance imaging (MRI) generates a host of biomarkers of the tumor environment, in particular for breast cancer, precious few (and typically only first-order markers) have been tested beyond single site studies with single workflow processing. To address both the need for advanced tissue characterization and multi-site translation, we propose a multi-site study of intravoxel incoherent motion (IVIM) MRI in breast cancer to determine its maximum translational prognostic benefit. The IVIM model, which includes separate markers of tissue cellularity, vascular volume, and micro-vascular flow, has been successfully applied in a range of cancers, including breast cancer by the project teams of this proposal. This project will determine inherent variability of the technique with hardware variation (3 vendors) and software platforms (6 packages), in a 5 site retrospective analysis of clinical breast cancer IVIM data. We will then conduct a prospective two-site IVIM longitudinal study of patients undergoing neoadjuvant chemotherapy to determine the best pre- or mid-treatment biomarkers to predict therapeutic response. At each stage, performance will be evaluated both within each site and in the combined cohort, with the goal of identifying biomarkers that are both useful and broadly translatable.

Key facts

NIH application ID
10084095
Project number
1UG3CA239861-01A1
Recipient
NEW YORK UNIVERSITY SCHOOL OF MEDICINE
Principal Investigator
Eric Edward Sigmund
Activity code
UG3
Funding institute
NIH
Fiscal year
2021
Award amount
$395,274
Award type
1
Project period
2021-04-01 → 2023-03-31